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entiation of both of them conﬁrmed by staining with Oil Red O and
Alizarin Red respectively. We carried out RT-PCR and immunohis-
tochemistry analysis to test expression of SOX9, type II collagen,
type I collagen and C-20 aggrecan which are proteoglycan com-
pounds of extra-cellular matrix and all of them were positive as
soon as after 4 days in culture. Expressions of type X collagen
and MMP-13 proteins also were measured raising their expression
as well as increase the time in culture.
Figure 1. COL1, COL2 and COLX gene expression by RT-PCR of spheroids
produced at 4, 7, 14, 28 and 46 days using our chondrogenic medium.
Conclusions: Join together our results strongly suggest that the
MSC pool from umbilical cord stromal tissue is an excellent source
of cells susceptible to differentiate to chondrocyte-like cells which
could be a new cellular therapy against cartilage degradation.
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Purpose: To determine if the anti-osteoarthritis drug, pentosan
polysulfate (PPS), promoted proliferation and chondrogenic differ-
entiation of mesenchymal precursor stem cells (MPC) in vitro.
Methods: Human STRO-3+ MPC were maintained in monolayer
or micromass cultures (mmc) for up to 10 days in the absence
and presence of PPS at concentrations of 0.1, 0.5, 1.0, 2.5, 5.0,
10.0, and 20 μg/ml. MPC proliferation and viability was assessed
using the WST-1 mitochondral dehydrogenase cleavage assay
and by the incorporation of 3H-Thymidine into macromolecular
DNA in both culture systems. The capacity of PPS to protect
MPC from IL4/INF-γ induced apoptosis was also evaluated using
ﬂow cytometry. Proteoglycan (PG) biosynthesis was monitored
in mmc by the incorporation of 35SO4 into glycosaminoglycans
(35S-GAGs) on days 4, 5 and 6 post culture initiation. The relative
stimulatory effects of hyaluronan (HA) or dextran sulfate (DS)
on PG synthesis was also examined and compared to PPS in
day 5 mmc. The effects of PPS on the levels of bound and
unbound HA in MPC in mmc was quantiﬁed by an ELISA and
the deposition of type II collagen in the matrix assessed using
a COL-II Mab and immuno-staining of the ﬁxed cultures on day
10. The ability of PPS to modulate MPC osteogenic or adipogenic
differentiation was investigated by co-culturing the cells in the
respective inductive culture media for 28 days. Gene expression
by MPC in micromass cultures was determined on days 7 and 10
by Real Time and RT-PCR.
Results: On applying the WST-1 assay to day 6 monolayer cul-
tures it was found that PPS markedly stimulated MPC proliferation
with signiﬁcant effects being observed at concentrations of 1–10
μg/ml (p<0.01). However, DNA synthesis by MPC after 4 days
in mmc, showed a maximal stimulation by PPS at 1–2.5 μg/ml
(p<0.005). A 38% reduction in MPC apoptosis was obtained in the
presence of 1–10 μg/ml PPS. In 4–5 day MPC mmc, 5 μg/ml PPS
stimulated PG synthesis by 100% more than control (p<0.005)
while HA and DS at 5 μg/ml and greater inhibited PG synthesis
(p<0.005). In 10 day MPC mmc, PPS promoted maximal Type II
collagen deposition in the matrix at 5 μg/ml while maximal de-
position of HA, relative to controls, occurred with 20 μg/ml PPS
(p<0.005). The results of the bioassays examining cartilage matrix
production by MPC in the presence of PPS were supported by the
Real Time and RT-PCR gene expression studies using primers for
Aggrecan, COL-II, SOX-9 and other genes. Notably, while able to
stimulate chondrogenic differentiation of MPC, PPS at concentra-
tions in excess of 1.0 μg/ml inhibited osteogenic differentiation of
MPC (p<0.01).
Conclusions: These results conﬁrmed that PPS at low in-vitro
concentrations promoted early proliferation and chondrogenesis
of MPC while also blocking its potential to undergo osteogenic
differentiation. On the basis of the published literature and our
preliminary unpublished ﬁndings we propose that the promotion of
MPC chondrogenesis by PPS may be mediated by the ability of
this agent to enhance degradation of IGFBP-3 by ADAM-12s.
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Purpose: Osteoarthritis (OA) is a multifactorial disease charac-
terized by destruction of the articular cartilage due to environ-
mental, mechanical and genetic components. The genetics of OA
is complex and is not completely understood. Recent work has
demonstrated the importance of microRNAs (miRNAs) in carti-
lage function. MiRNAs are a class of small noncoding RNAs that
regulate gene expression and are involved in different cellular
process: apoptosis/proliferation, development, glucose and lipid
metabolism.
The aim of this study was identify and characterize the expres-
sion proﬁle of miRNAs in normal and OA chondrocytes and to
determine their role in the chondrocyte biology.
Methods: Chondrocytes were obtained from 1 healthy donor and
from 1 OA patient. After the ﬁrst passage, the cells were moved
to aggregate culture for a week. Evaluation of in vitro aggregate
culture was carried out using histochemical (hematoxylin-eosin,
Alcian Blue, Safranin O and Masson Tricromic) and immunohis-
tochemical (Aggrecan, Collagen Type I and II) stainings. MicroR-
NAs were extracted with miRVana Isolation kit and analyzed at
the CNIO Core Facilities (Madrid, Spain) using the Agilent Hu-
man miRNA Microarray. Raw microarray data were normalized
and analyzed using Agilent FeatureExtraction (FE) Software and
GeneSpring GX10. Of the 723 human miRNAs, a list of the differ-
entially expressed miRNAs in normal and OA chondrocytes was
bioinformatically analyzed (using Sanger miRBase, microRNA.org,
